New GLP-1 Complaint Alleges Novo Nordisk Failed to Warn of Ileus Risks
A new complaint in the GLP-1 multidistrict litigation accuses Novo Nordisk of failing to warn patients about the risk of ileus and intestinal obstruction from Ozempic.
Life Sciences & Pharma
Most Significant
Recent Articles
New GLP-1 Complaint Alleges Novo Nordisk Failed to Warn of Ileus Risks
A new complaint in the GLP-1 multidistrict litigation accuses Novo Nordisk of failing to warn patients about the risk of ileus and intestinal obstruction from Ozempic.
Judge Lin Dismisses J&J Risperdal Lawsuit, Citing Statute of Limitations and Preemption
A Northern District of California judge dismissed a products liability lawsuit against Johnson & Johnson and Janssen Pharmaceuticals, ruling that plaintiffs failed to plead when their mother was exposed to Risperdal or discovered her cancer, leaving...
Judge Cummings Denies BeiGene’s Motion to Dismiss AbbVie Trade Secret Suit
AbbVie’s trade secret suit against BeiGene survives a motion to dismiss, with the court finding the complaint plausibly alleged the company took reasonable measures to protect its cancer drug designs and described them with sufficient specificity.
AstraZeneca Loses Bid to Dig Into Missouri Hospitals' 340B Drug Revenue
A federal judge ruled the drugmaker's subpoenas to six hospital systems were irrelevant to its Contract Clause challenge to Missouri's law protecting contract pharmacy access to 340B discounts.
District Court Holds STOLI Policy Void Ab Initio, Denying Restitution to Securities Intermediary
The District of Delaware granted summary judgment to Ameritas Life Insurance Corp., holding that a $10 million life insurance policy on Irene Sloat was void from inception because it lacked an insurable interest under Delaware law. The court also denied...
Third Circuit Affirms Denial of Injunction in Janssen-Samsung Stelara Biosimilar Dispute
The Third Circuit on Friday upheld a district court's refusal to enjoin Samsung Bioepis from supplying a Cigna subsidiary with a private-label version of the ustekinumab biosimilar Pyzchiva, holding that Johnson & Johnson and Janssen Biotech had not...